New Triple-Targeting drug enters first human tests for tough blood cancers
NCT ID NCT07294300
Summary
This is a first-in-human study to test the safety and early effectiveness of a new experimental drug called QLS2313 in adults with blood cancers that have returned or stopped responding to standard treatments. The study will find the safest dose and look for early signs that the drug can fight cancer. It is for patients with specific B-cell blood cancers who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Jiaotong University School of Medicine Ruijin Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.